Jubilant Pharmova Limited (NSE:JUBLPHARMA)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Radio Pharma	36.90B	33.88B	30.01B	25.52B	21.23B
Allergy Immunotherapy	7.96B	7.14B	6.98B	6.03B	4.89B
Contract Development and Manufacturing Organization - Sterile Injectables	18.13B	13.53B	12.04B	12.71B	14.35B
Contract Research, Development and Manufacturing Organization	12.65B	11.73B	11.40B	12.93B	11.48B
Generics	7.74B	6.85B	7.75B	7.65B	11.62B
Inter-Segment Revenue	-1.16B	-1.16B	-1.53B	-2.28B	-2.49B
Unallocable Corporate	585.00M	372.00M	383.00M	218.00M	202.49M
Proprietary Novel Drugs	-	-	-	38.00M	18.41M
Total	82.80B	72.35B	67.03B	62.82B	61.30B

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
India	2.46B	2.13B	1.92B	1.91B	3.39B
Americas and Europe	76.07B	65.94B	60.12B	55.94B	53.19B
Rest of The World (ROW)	4.27B	4.28B	4.99B	4.98B	4.71B
Total	82.80B	72.35B	67.03B	62.82B	61.30B

Data Source: S&P Global Market Intelligence Last updated: Aug 10, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 11, 2026

Data Sources Report a data error